臺灣博碩士論文加值系統

肺癌是全球不分性別，並且在全球所有癌症之加總下，佔據高達11.6%發生率的癌種。而以致死率來看，肺癌更至高至佔據了癌症總死亡人數的18.4%。根據衛生福利部國民健康署更新至2020年6月的資料所顯示，臺灣前十大癌症發生的常見度，肺癌便佔據了不做男女的性別區分的第二名。在免疫檢查點抑制劑的免疫治療方式問世之前，癌症的治療不外乎手術的物理切除、放療、化療、標靶治療等方式。然而在2013年之後，免疫治療成為了抗癌的第五種新武器，而免疫檢查點抑制劑療法的兩位發明者更是在2018年得到了諾貝爾生理學暨醫學獎。有鑑於此，本研究著重於探討臺灣肺癌免疫檢查點抑制劑治療的現況以及在台灣未來市場的前景，並且使用PESTEL分析、SWOT 分析以及五力分析評估肺癌免疫檢查點抑制劑之市場競爭力及未來市場優劣。並透過分析後得出免疫檢查點抑制劑在台灣對於肺癌的治療市場仍是處於藍海，並處於樂觀成長的階段。並且根據分析所得的結論，針對醫療人員、藥物開發企業、以及相關政策制定部門等三個種類單位給予肺癌免疫檢查點抑制劑未來發展之相關意見。

According to the Health Promotion Administration, Ministry of Health and Welfare’s data, the latest update in June 2020, among the ten most common cancers in Taiwan, lung cancer occupies the second place regardless of gender differentiations. Before the cancer immunotherapy, such as the invention of the immune checkpoint inhibitors, was introduced, the most common treatments for cancer were physical resection of surgery, radiotherapy, chemotherapies, and targeted therapies. Yet, the innovative cancer immunotherapy has become the fifth weapon fighting against cancers since 2013, with the two inventors of immune checkpoint inhibitor therapy winning the Nobel Prize in Physiology and Medicine in 2018. With this in mind, this research focuses primarily on an exploration of the current lung cancer immune checkpoint inhibitor therapy and its future market prospects in Taiwan, while applying PESTEL analysis, SWOT analysis, and the Porter Five Forces analysis to evaluate the market competitiveness of the lung cancer immune checkpoint inhibitors and its future market’s advantages and disadvantages. Through various analyses, the result demonstrates that Taiwan’s immune checkpoint inhibitors market for the treatment of lung cancer is still a Blue Ocean Market, a stage suggesting its optimistic growth.

國立臺灣大學碩士學位論文 i
口試委員會審定書 i
誌 謝 ii
中文摘要 iii
Abstract iv
第一章 緒論 1
第一節 研究背景與動機 1
第二節 研究目的 10
第三節 研究問題 11
第四節 研究方法 12
第二章 文獻探討 14
第一節 PESTEL分析模型 14
第二節 SWOT 分析矩陣模型 16
第三節 五力分析 17
第三章 肺癌治療相關產業分析 21
第一節 肺癌在臺灣之現況 21
第二節 肺癌治療方式 25
第三節 免疫檢查點抑制劑 27
第四節 免疫檢查點抑制劑之特性 29
第五節 免疫檢查點抑制劑全球趨勢 33
第六節 免疫檢查點抑制劑臺灣現況 35
第四章 肺癌治療之市場分析 39
第一節 國內醫療市場之需求 39
第二節 國內之競爭狀況 47
第三節 小結 50
第五章 結論與討論 52
第一節 主要發現 52
第二節 實務與政策意涵 53
第三節 研究限制 56
第四節 未來研究方向 57
參考文獻 58

衛生福利部中央健康保險署(2011)．2011-2012全民健康保險年報。https://www1.nhi.gov.tw/Nhi_E-LibraryPubWeb/CustomPage/P_Detail.aspx?FType=8&CP_ID=163
衛生福利部國民健康署(2017)．2017癌症登記報告。https://www.hpa.gov.tw/Pages/List.aspx?nodeid=119
衛生福利部國民健康署(2020)．2020衛生福利部公布癌症發生資料。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4141&pid=12682
陳偉武、洪敏瑛、陳幼貴(2010)．肺癌治療回顧及發展．腫瘤護理雜誌，10(2)，39-54。https://doi.org/10.6880/TJON.201012_10(2).04
陳欽銘(2006)．肺癌中西醫治療現況及展望．中醫藥研究論叢，9(2)，19-35。https://doi.org/10.6516/TJTCM.200609_9(2).0002
葉育雯(2013)．最新肺癌之診斷與治療．最新肺癌之診斷與治療，57(4)，36-38。
財團法人癌症希望基金會(2020)．希望之路-面對肺癌 (十七版一刷)．臺北市:財團法人癌症希望基金會
衛生福利部中央健康保險署(2020年，9月21日)．癌症免疫檢查點抑制劑新藥健保給付問答集。https://www.nhi.gov.tw/Content_List.aspx?n=7157A9A3E2A3B110&topn=3FC7D09599D25979)
國家衛生研究院(2004)．肺癌臨床指引．TCOG肺癌研究委員會
陳偉武、洪敏瑛、陳幼貴(2010)．肺癌治療回顧及發展．腫瘤護理雜誌，10(2)，39-54。
李英芬、蔡麗雲、劉景萍(2005)．癌末病人之疲倦及其相關因素．安寧療護理雜誌，10(3)，258-271。
李芸湘、蔡芸芳、賴裕和、高瑞和(2002)．肺癌病人在化學治療期間疲憊程度及其相關因素．臺灣醫學，6(6)，797-804。
余忠仁（2020）．完全解析肺癌診治照護全書．原水文化。
李佳欣(2019)．頭頸癌：免疫治療提高兩倍存活率．台灣癌症基金會。
張茗喧(2019)．百憂解不堪健保砍藥價4月退出台灣市場．中央社。
朱柔若(2000) ．社會研究方法：質化與量化取向．揚智。
歐陽晉佑（2012）．以PEST模型分析越南吸引外來投資之因素─以台商為例。國立中山大學中國與亞太區域研究所碩士論文。
李永翎(2007)．三江源自然保護區生態旅遊開發的SWOT分析．青海民族研究。18(4)，178-180。
陳錦憲(2008) ．以平衡計分卡做為策略規劃工具之研究 – 以 H 公司為例。國立交通大學．碩士論文。
方至民(2000)．企業競爭優勢．前程企業管理公司。
黃國埕(2018)．免疫檢查點抑制劑在癌症治療的發展與應用．腫瘤護理雜誌， 18(1)，13-26。https:// doi: 10.3966/168395442018061801002
衛生福利部中央健康保險署(2019)．癌症免疫藥品續用或結案情形。https://www.nhi.gov.tw/Content_List.aspx?n=7157A9A3E2A3B110&topn=3FC7D09599D25979
行動基因(2020)．我適合做癌症免疫治療嗎?。http://www.actgenomics.com/tw/clinical_news/201805-cancer-immunotherapy
寇怡衡(2016)．癌症免疫療法商機無限．環球生技月刊，6
寇怡衡、陳秋玲(2016)．免疫療法之抗癌商機探討．生物技術。
Griffin Ricky W. (1999)．基礎管理學 (方世榮譯)．台灣東華書局股份有限公司。
Gogo Partners 夥伴行銷(2021) ．行銷寶典來了！想利用行銷策略來規畫行銷流程，看這篇就對了！。https://blog.gogopartners.com/%E8%A1%8C%E9%8A%B7%E4%BC%81%E5%8A%83-%E8%A1%8C%E9%8A%B7%E7%AD%96%E7%95%A5#%E4%BD%95%E8%AC%82%E8%A1%8C%E9%8A%B7%EF%BC%9F
Michael.E.Porter. (1999)．Strategy Management (黃營杉譯)．新陸書局。
Hill.C.W, G.R.Jone. (1998)．Strategic Management Theory (黃營杉譯)．華泰書局。
韓婷婷(2017)．北極星發表新研究 羅氏藥廠合作臨床試驗．中央社。
行政院 (2020年，10月28日)．加速生技醫療產業創新—打造臺灣成為國際生醫
創新研發樞紐。https://www.ey.gov.tw/Page/5A8A0CB5B41DA11E/fea217e2-81da-46bc-9fe5-55cfe66b53a0
Alberg, A. J., & Samet, J. M. (2003). Epidemiology of lung cancer. Chest, 123(1), 21S-49S.
Barney, J. B. 1995. Looking inside for competitive advantage. The Academy of Management Executive, 9(4), 49-62.
Berrino, F. (2013). Life style prevention of cancer recurrence: the yin and the yang. Advances in Nutrition and Cancer, 341-351.https://doi.org/10.1007/978-3-642-38007-5_20.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, T., & Jemal, A. (2018). Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.
CME. (2009). Lung Cancer：Diagnosis and Management (pp. 1-54). Sacramento, California：2009 CME Resource.
DeSilets, L. D. 2008. SWOT is useful in your tool kit. Journal of continuing education innursing, 39(5), 196-197.
Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer. Asia-Pacific journal of oncology nursing, 4(2), 127. https://doi.org/10.4103/apjon.apjon_4_17
Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., & Trotti, A. (Ed.).(2010). AJCC Cancer Staging Manual (7 ed.). New York: Springer-Verlsg
Enfu Hui (2019). Immune checkpoint inhibitors. Journal of Cell Biology, 218(3), 740-741. https://doi.org/10.1083/jcb.201810035
G Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., ... & Garassino, M. C. (2018). Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. New England journal of medicine, 378(22), 2078-2092.
Gift, A. G., Stommel, M., Jablonski, A., & Given, W. (2003). A cluster of symptoms overtime in patients with lung cancer. Nurs Res, 52(6), 393-400.
RNCOS E-Services Pvt. Ltd (2020). Global Immune Checkpoint Inhibitors Market Outlook 2022. https://www.giichinese.com.tw/report/rnc606409-global-immune-checkpoint-inhibitors-market-outlook.html
Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. Journal of Clinical Oncology, 26(3), 392-398.
Kunimasa, K., & Goto, T. (2020). Immunosurveillance and immunoediting of lung cancer: current perspectives and challenges. International journal of molecular sciences, 21(2), 597.
Lawrence, L. (2019). Percentage of Patients to Benefit From Immune Checkpoint Inhibitors Still Limited. https://www.cancernetwork.com/view/percentage-patients-benefit-immune-checkpoint-inhibitors-still-limited
Lin, S., Chen, Y., Yang, L., & Zhou, J. (2013). Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients. Journal of Clinical Nursing, 22(9-10), 1281-1290. https://doi.org/10.1111/ jocn.12228.
Iivanainen, S., & Koivunen, J. P. (2020). Possibilities of improving the clinical value of immune checkpoint inhibitor therapies in cancer care by optimizing patient selection. International journal of molecular sciences, 21(2), 556.
Maguire, R., Papadopoulou, C., Kotronoulas, G., Simpson, M. F., McPhelim, J., & Irvine, L. (2013). A systematic review of supportive care needs of people living with lung caner. European Journal of Oncology Nursing, 17(4), 449-464. https://doi.org/10.1016/ j.ejon.2012.10.013.
Michael Moore. (2007). Sicko. Dog Eat Dog Films.
NCCN. (2011). NCCN Clinical Practice in Oncology : Non-Small Cell Lung Cancer V.2.2011
Neuman, W. L. (2004). Basics of social research: Qualitative and quantitative approaches. Boston: Pearson.
Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12(4), 265-277.
Porter, M. E. (1985). The Competitive Advantage: Creating and Sustaining Superior Performance. NY: Free Press. (Republished with a new introduction, 1998.)
Porter, M. E. (1981). The contributions of industrial organization to strategic management. Academy of management review, 6(4), 609-620.
Porter, M. E., (1985). Competitive Advantage. NY: Free Press.
Mikelez-Alonso, I., Aires, A., & Cortajarena, A. L. (2020). Cancer ano-immunotherapy from the injection to the target: The role of protein corona. International journal of molecular sciences, 21(2), 519. https://doi.org/10.1007/978-3-642-38007-5_3.
Umesawa, M., Iso, H., Mikami, K., Kubo, T., Suzuki, K., Watanabe, Y., ... & Tamakoshi, A. (2014). Relationship between vegetable and carotene intake and risk of prostate cancer: the JACC study. British journal of cancer, 110(3), 792-796. https://doi.org/doi: 10.1038/bjc.2013.685
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., ... & Brahmer, J. R. (2016). Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N engl J med, 375, 1823-1833.
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., ... & Ramalingam, S. S. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. The lancet oncology, 16(3), 257-265.
Roviello, G., Corona, S. P., D’Angelo, A., Rosellini, P., Nobili, S., & Mini, E. (2020). Immune checkpoint inhibitors in pre-treated gastric cancer patients: results from a literature-based meta-analysis. International journal of molecular sciences, 21(2), 448.
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a cancer journal for clinicians, 68(1), 7–30. https://doi.org/10.3322/caac.21442
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: a cancer journal for clinicians, 69(1), 7-34. https://doi.org/10.3322/caac.21551
Silberstein, T., Silberstein, E., Saphier, O. (2013). Lycopene and tomatoes: Their effect on prevention of prostatic cancer. Pub Med, 152(8):461-3, 499.
Tishelman, C., Petersson, L. M., Degner, L. F., & Sprangers, M. A. G. (2007). Symptom prevalence, intensity, and distress in patients with inoperable lung cancer in relation to time of death. Journal of Clinical Oncology, 25(34), 5381-5389. https://doi.org/10.1200/ JCO.2006.08.7874.
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., ... & Sznol, M. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443-2454.